Adjuvant chemotherapy for soft XXXX : a 10-year mono-institutional experience.

@entity1 @entity137 @entity66 @entity242 @entity204 @entity1349
PURPOSE: The role of adjuvant chemotherapy (ACT) for soft @entity242 (STS) is not standard practice. We investigated effectiveness and tolerability of ACT in @entity1 (pts) with operated high-risk STS in clinical practice. METHODS: Medical records of pts with localized STS referred to Istituto Oncologico Veneto, Padova, from January 1, 2003 to July 07, 2012 were reviewed. Data were collected for pts with high-risk STS (size >= 5  cm, high grade and stage III). For those who received ACT, regimens used, drug doses, number of cycles, @entity137 , and reasons for dose reduction or treatment interruption were recorded. Disease-free survival (DFS) and @entity1349 ( @entity1349 ) were calculated with the Kaplan-Meier method. RESULTS: Out of 96 eligible pts, median age 62  years, 36 received ACT after loco-regional treatment. Median DFS was 29.6  months (95  % CI 13.2-46.0) in pts receiving ACT and 7.8  months (95  % CI 3.9-11.7) in untreated pts (p  <  0.0001); median @entity1349 was 67.0  months (95  % CI 25.4-108.6) in treated and 33.7  months (95  % CI 23.3-44.2) in untreated pts (p  =  0.005). Among pts receiving ACT, a significant difference in DFS was observed between pts with limb/ @entity66 (median DFS 82.4  months; 95  % CI 0.0-184.7) and pts with other primary sites (median DFS 18.3  months; 95  % CI 8.0-28.5) (p  =  0.052). Grade >= 3 @entity137 occurred in 20 pts (20.8  %), leading to dose reductions, delays, and treatment discontinuation in five cases. There was no treatment-related @entity204 . CONCLUSION: Our data confirm benefit of ACT with regard to DFS and @entity1349 in pts with high-risk STS, greatest for limb/girdle STS.
